Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Interim report January-June 2019

April-June 2019 · Net sales were 348.2 MSEK (313.6), an increase of 11.0% from the equivalent quarter in 2018. · Operating income increased to 32.1 MSEK (22.0), an operating margin of 9.2% (7.0). · Earnings per share were 1.63 SEK (1.26). · Cash flow after investments was -114.1 MSEK (18.1). January-June 2019 · Net sales were 647.5 MSEK (593.6), an increase of 9.1% from the equivalent period in 2018. · Operating income increased to 71.6 MSEK (38.8), an operating margin of 11.1% (6.5). · Earnings per share were 3.90 SEK (2.24). · Cash flow after investments was

YIT signs a contract on the construction of the Keravanjoki multipurpose building

YIT Corporation      Investor News      August 23, 2019 at 9.00 a.m.YIT, as part of an alliance, has signed a contract on the construction of the Keravanjoki multipurpose building in Kerava, Finland. YIT’s role in the alliance is contractor. The total value of the project is approximately EUR 36 million, of which YIT’s share is approximately EUR 25 million. The contract will be entered in the order backlog of this year’s third quarter. City of Kerava decided on the implementation of the alliance project  The City of Kerava has decided on the construction of the new Keravanjoki

Interim report April-June 2019

Mölndal, August 23, 2019 – Vicore Pharma Holding (publ) publish the interim report for the second quarter 2019.Important events during the second quarter · In April, Vicore Pharma announced that it has selected the disease diffuse systemic sclerosis (dSSc) as the second indication for its lead program VP01 (C21). It complements the primary indication, idiopathic pulmonary fibrosis (IPF) Important events after the period · No significant events have taken place after the period. Financial overview for the periodApril 1 - June 30, 2019 · Operating income amounted to 0.0

Axolot Solutions Holding AB Interim report January 1 - June 30, 2019

START-UP OF BUSINESS WITH IMPORTANT PLAYERSThe second quarter 2019 at a glance · Net sales amounted to 607 tsek (276 tsek for the corresponding quarter in 2018) · Other revenues, referring to subsidies from a Finnish state agency, were 107 tsek (0) · Earnings before interest and tax became -7 604 tsek (-4 197), including provision for severance pay -1 030 tsek · Net earnings per share amounted to -0,29 sek (-2,20) · Delivery and start-up of recently completed mobile pilot equipment for important players within pisciculture, decontamination, agriculture and the forest & pulp

Last day of trading in subscription rights and last day of the subscription period for the subsequent offering

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN, OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN. Reference is made to the previous announcements by Norwegian Energy Company ASA (the "Company") regarding the subsequent offering of minimum 1,326,486 new shares and maximum 1,768,648 new shares in the Company at a subscription price of NOK 185 per new share (

Kamux Corporation’s Half Year Financial Report for January 1-June 30, 2019

Kamux Corporation         Half Year Financial Report                  August 23, 2019 at 09:00 Kamux Corporation’s Half Year Financial Report for January 1-June 30, 2019 Kamux’s revenue increased by 22.9% and adjusted operating profit continued to increase The figures in parenthesis refer to the comparison period, i.e. the same period in the previous year, unless stated otherwise. April-June in brief - The number of cars sold increased by 17.6% to 13,441 cars (11,433) - Revenue increased by 22.9%, totaling EUR 157.3 million (128.0) - Gross profit increased by 23.4% to

SaltX Technology Holding AB (publ) Interim report 2, 2019

Interim report 2  Financial eventsQuarter 2-Net sales totaled MSEK 0.9 (1.8)-Operating profit/loss (EBIT) amounted to MSEK -45.8* (-15.9)-Cash flow from operating activities amounted to MSEK -10.5 (-16.9)-Earnings per share before and after dilution were SEK -1.38 (-0.14) Full year January — June-Net sales totaled to MSEK -0.8 (3.3)-Operating profit/loss (EBIT) amounted to MSEK -65,9 (-29.7) -Cash flow from operating activities amounted to MSEK -35.6 (-29.1)-Earnings per share before and after dilution were SEK -0.96 (-0.50) Significant events Second quarter-

Conditions for Söderport's sale of properties to Torslanda Property Investment fulfilled

As announced through a press release on July 10, 2019, Nyfosa's joint venture Söderport Holding AB, which is owned equally by Nyfosa and Sagax, has agreed to transfer six properties in Torslanda to the listed one-property company Torslanda Property Investment AB ("TPI"). The transaction was subject to approval by the Extraordinary General Meeting of TPI. At the Extraordinary General Meeting on August 22, 2019, the transaction was approved and the condition for the transaction is thus fulfilled. Closing date is expected to take place on October 1, 2019.

Interim Report, January–June 2019

Important Customer Agreements and Financing of Ovzon 3 April–June 2019 Quarter · Revenue amounted to 55,987 TSEK (57,092). · Operating profit totalled -9,049 TSEK (-11,966). · Operating profit excluding items affecting comparability amounted to 3,248 TSEK (2,057). · Profit after tax amounted to -12,915 TSEK (-15,051). · Earnings per share amounted to -0.38 SEK (-2.25). January–June 2019 Period · Revenue amounted to 109,348 TSEK (103,403). · Operating profit totalled -4,389 TSEK (-23,589). · Operating profit excluding items affecting comparability amounted

Lung Bioengineering has acquired the XPS™ for use in its new Jacksonville EVLP center

Lung Bioengineering Inc., a subsidiary of United Therapeutics Corporation (NASDAQ: UTHR), has purchased an XVIVO Perfusion System (XPS™) with STEEN Solution™ Perfusate to use in its new ex vivo lung perfusion (EVLP) center in Jacksonville, Florida. Lung Bioengineering previously purchased an XPS™ to use in its EVLP center in Silver Spring, Maryland in 2018. The aim of the new EVLP center in Jacksonville is to reduce the shortage of transplantable lungs through the use of a centralized organ evaluation service.Lung Bioengineering purchased an XVIVO Perfusion System (XPS™) with STEEN Solution

Invitation to Nixu’s Capital Markets Day on September 26, 2019

Nixu CorporationPress release, August 23, 2019 at 9 am EESTEuropean cybersecurity company Nixu is pleased to invite investors, analysts and media to its Capital Markets Day, to be held on Thursday, September 26, 2019 at the Nixu office in Finland (address: Keilaranta 15, Espoo). The purpose of the Capital Markets Day is to provide information on the progress of Nixu’s growth strategy and its targets, and the overall development of the cybersecurity market. Additional the event will include demonstrations of cybercriminal actions. The event registration opens and coffee is served at

Interim Report January–June 2019

“On 5 June, John Mattson was listed on Nasdaq Stockholm, Mid Cap, a key milestone in the company’s history. In conjunction with the listing process in the spring, progress has been made on projects aimed at adding value and infill development,” comments Siv Malmgren, CEO of John Mattson.·  Rental revenues totalled SEK 124.9 million (96.4), up 30%. ·  Income from property management was SEK 20.5 million (8.2), corresponding to SEK 0.61 per share (0.27). ·  During the period, non-recurring costs linked to the completed stock exchange listing of SEK 9.9 million (4.4) were recognised

Quarterly report Scandinavian Enviro Systems AB (publ) January – June 2019

N.B. The English text is an in-house translation of the original Swedish text. Should there be any disparities between the Swedish and the English text, the Swedish text shall prevail.Enviro’s receives its biggest order until now from Trelleborg Q2 2019 ·  Net revenues for the period were MSEK 0.2 (0.4)  ·  Earnings after tax for the period were MSEK -11.4 (-9.9)   ·  Earnings per share for the period (before dilution) was SEK -0.03 (-0.08)   ·  Cash flow for the period after investments was MSEK -11.4 (-7.9)  ·  Trelleborg Lanka places a serial sales order amounting to

Key information relating to the preferential rights issue to be carried out by Nordic Mining ASA

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, JAPAN OR THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN.Date on which the terms and conditions of the preferential rights issue were announced: On or about 12 September 2019 Last day including right: 13 September 2019 Ex-date: 16 September 2019 Record Date: 17 September 2019 Date of approval: 13 September 2019

Proposed Rights Issue and Summons for Extraordinary General Meeting on 13 September 2019

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, JAPAN OR SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN.The Board of Directors of Nordic Mining ASA ("Nordic Mining" or the "Company") has today resolved to call for an extraordinary general meeting in the Company on 13 September 2019 to resolve, among other things, a rights issue of approximately NOK 35 million (the "Rights Issue").

Communiqué from extraordinary general meeting in Dicot AB (publ)

An extraordinary general meeting in Dicot AB (publ) was held on 22 August 2019 at Advokatfirman Lindahl’s office on Vaksalagatan 10 in Uppsala whereby the shareholders resolved on the following matters.Resolution to amend the company’s articles of association The extraordinary general meeting resolved to amend the company’s articles of association with respect to the limits of the company’s share capital (section four) and the limits of the number shares in the company (section five) in accordance with the following. Current wording 4. Aktiekapital Aktiekapitalet skall vara

Second quarter Interim report January - June 2019

Stable sales - in line with a strong second quarter last year 1 April – 30 June 2019 · Net sales amounted to SEK 3,100 M (1,633). Net sales rose 90 per cent, of which 0 percentage points is organic growth. · Adjusted EBIT amounted to SEK 280 M (217). · EBIT totalled SEK 240 M (173) and the EBIT margin was 8 (10) per cent. EBIT was not impacted by items affecting comparability in the quarter (negative SEK 25 M). · Positive impacted of IFRS 16 of SEK 5 M on EBIT and adjusted EBIT. · Earnings per share, before and after dilution, amounted to SEK 2.71 (3.53). · Cash flow

Invitation to Presentation of Promore Pharma’s Interim report for the second quarter 2019

STOCKHOLM, 23 August 2019 – Promore Pharma AB (publ) publishes its Interim report for the second quarter 2019 at 14.00 CET on 28 August 2019.The next day, 29 August, the company will host a webcast telephone conference at 10.00 CET, with President and CEO Jonas Ekblom and CFO Jenni Björnulfson. After the presentation there will be a Q&A session. The presentation will be held in English. The conference can be accessed via computer, tablet or telephone.   To join the web conference, please use the following link: https://global.gotomeeting.com/join/494286021 To join the telephone

Interim report January-June 2019

Strong sales growth during the second quarterSecond quarter[1] ·  Consolidated net sales increased by 45.4 per cent to SEK 91.2 million (62.7).   ·  Operating profit (EBIT) increased by SEK 4.5 million to SEK 3.4 million (loss 1.0).  ·  Earnings per share after dilution amounted to SEK 0.05 (loss 0.01).   First six months of the year[1]  ·  Consolidated net sales increased by 36.3 per cent to SEK 176.1 million (129.2).   ·  Operating profit (EBIT) increased by SEK 9.8 million to SEK 13.8 million (4.0).  ·  Earnings per share after dilution amounted to SEK 0.36 (0.13)

Navamedic ASA: Q2 and first half 2019 financial results

Oslo, 23 August 2019 – Navamedic ASA (OSE: NAVA) continues to grow and reported revenues of NOK 47.2 million in the second quarter of 2019, up 4.4% from the same period in 2018. The company’s EBITDA came in at NOK 0.9 million (NOK 5.6 million in the second quarter of 2018), mainly due to project costs related to the demerger of Medtech, and increased focus on business development. The demerger and separate listing provide a platform for accelerated growth in both Pharma and Medtech.   “We have initiated the implementation of the new growth strategy and see a great potential in leveraging

Kojamo plc: Kojamo plc’s Half-Year Financial Report 1 January – 30 June 2019

Kojamo Plc Stock Exchange Release, 23 August 2019 at 8:00 a.m. EESTKojamo plc’s Half-Year Financial Report 1 January – 30 June 2019 Profitable growth in line with strategy during the first half of the year This is a summary of the Half-Year Financial Report January–June 2019, which is in its entirety attached to this release and can be downloaded from the company’s website at www.kojamo.fi/investors. Unless otherwise stated, the comparison figures in brackets refer to the corresponding period of the previous year. The figures in this Half-Year Financial Report have not been audited.

Catella AB – Interim Report January-June 2019

Total income amounted to SEK 688 M in the second quarter 2019, up 14% year-on-year. The second quarter 2019 was one of Catella’s strongest in terms of earnings and operating profit which amount to SEK 164 M, corresponding to an increase of 38% on the second quarter 2018. The historical initiatives we’ve completed to date, which have focused on growing assets under management, have paid off in the quarter. Both fixed earnings and the potential provided by our earnings model in the form of variable earnings are now feeding through to profit. This is despite the absence of variable earnings in

Saab to continue supporting Australian Army’s GBAD and C-RAM capability

Saab has received an order from the Australian Army to extend the support of their Ground Based Air Defence (GBAD) and Counter Rocket, Artillery and Mortar (C-RAM) systems until 2022. This ensures the availability and effectiveness of these important capabilities, which are fielded by 16th Regt, Royal Australian Artillery.Under the contract Saab will provide support for the range of systems forming the GBAD and CRAM solutions, including the Giraffe Agile Multi-Beam (AMB) radars and RBS-70 very short-range air defence weapon system. The contract value is approximately SEK 184 million. “

SimCorp reports revenue growth of 21% and EBIT margin of 28% in H1 2019 with eight new clients signed and has upgraded its 2019 financial guidance

Company announcement no. 41/2019 Q2 2019 highlights: · A strong Q2 2019 with signing of four new SimCorp Dimension and two new SimCorp Coric orders, led to reported Q2 2019 revenue of EUR 109.5m. When compared with Q2 2018, an increase of 32.0%, and measured in local currencies, an increase of 30.1%. · EBIT of EUR 32.3m and EBIT margin of 29.5% compared with EBIT of EUR 14.0m and EBIT margin of 16.9% in Q2 2018. Measured in local currencies EBIT margin was 29.0%. · Order intake was EUR 22.6m, an increase of EUR 6.4m or 39.5% compared with Q2 2018. H1 2019 highlights: ·

There are no items matching the current filter
There are no more items matching the current filter
Back to top